EXACT Sciences Co. (NASDAQ:EXAS) insider Graham Peter Lidgard sold 6,125 shares of EXACT Sciences stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $50.94, for a total value of $312,007.50. Following the completion of the transaction, the insider now owns 200,074 shares of the company’s stock, valued at approximately $10,191,769.56. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Graham Peter Lidgard also recently made the following trade(s):
- On Wednesday, February 28th, Graham Peter Lidgard sold 39,884 shares of EXACT Sciences stock. The shares were sold at an average price of $43.10, for a total value of $1,719,000.40.
Shares of EXACT Sciences Co. (NASDAQ:EXAS) opened at $52.76 on Thursday. The firm has a market capitalization of $6,355.48, a P/E ratio of -52.76 and a beta of 0.71. EXACT Sciences Co. has a 52 week low of $19.91 and a 52 week high of $63.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.77 and a current ratio of 7.15.
EXAS has been the subject of several recent research reports. Bank of America lifted their price objective on EXACT Sciences from $58.00 to $67.00 and gave the company a “buy” rating in a research note on Wednesday, November 29th. BidaskClub cut EXACT Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 6th. William Blair reiterated a “buy” rating on shares of EXACT Sciences in a research note on Tuesday, January 2nd. Zacks Investment Research upgraded EXACT Sciences from a “hold” rating to a “buy” rating and set a $62.00 target price for the company in a research note on Tuesday, January 16th. Finally, Benchmark set a $65.00 target price on EXACT Sciences and gave the stock a “buy” rating in a research note on Wednesday, January 17th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $52.84.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Columbus Circle Investors increased its position in EXACT Sciences by 5.5% during the third quarter. Columbus Circle Investors now owns 133,398 shares of the medical research company’s stock worth $6,286,000 after buying an additional 6,965 shares during the period. Emerald Advisers Inc. PA acquired a new position in EXACT Sciences during the fourth quarter worth approximately $21,813,000. Advisors Management Group Inc. ADV acquired a new position in EXACT Sciences during the third quarter worth approximately $317,000. Pacer Advisors Inc. acquired a new position in EXACT Sciences during the third quarter worth approximately $905,000. Finally, Brown Advisory Inc. acquired a new position in EXACT Sciences during the third quarter worth approximately $368,000. 82.05% of the stock is currently owned by institutional investors.
EXACT Sciences Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.